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Abstract: Carcinoembryonic antigen and vascular endothelial growth factors are among the most important prognostic 
markers of colorectal cancer. Testing for these markers independently has been of limited value in screening for this tu-
mor. The aim of this study is to determine the importance of simultaneous blood CEA and VEGF level determinations in 
diagnosis of colorectal cancer. Thirty-six patients diagnosed with colorectal cancer along with eight healthy controls were 
tested by ELISA for CEA and VEGF levels in serum and plasma, respectively. The positive predictive value of these 
markers was 95.4% for CEA and 89.5% for VEGF, and for combined CEA and VEGF was also high at 88%. Combined 
CEA and VEGF blood level assay constitutes a useful panel in detecting patients with colorectal cancer. Positive results 
allow selection of a subgroup of patients with a high tumor risk; therefore, such tests comprise valuable tumor diagnostic 
tests to add to current detection methods. 
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INTRODUCTION 
  Colorectal cancer is the second most prevalent cancer 
and the fourth leading cause of death [1]. In Lebanon, it is 
the second most frequently diagnosed cancer in women and 
the fourth most frequent cancer in men; with a yearly inci-
dence of about 12 cases per 100,000 individuals [2, 3]. The 
literature on colorectal cancer in Lebanon is limited and 
mostly related to its epidemiology. The tumor tends to be 
diagnosed in its late stages, which underscores the need for 
more effective detection methods [4-6]. 
  Advances in molecular medicine, specifically in the areas 
of gene expression and proteomics have made it possible to 
correlate disease stages with molecular marker profiles. In 
the case of colorectal cancer, a wide variety of molecular 
markers have been studied. These studies have mainly fo-
cused on carcinoembryonic antigen (CEA), and more re-
cently on vascular endothelial growth factor (VEGF), both of 
which are found in body fluids including serum and plasma 
[7-9]. 
  Carcinoembryonic antigen (CEA) is a glycoprotein with 
a molecular weight of approximately 200 kDa [10, 11]. This 
antigen is expressed in a number of normal tissues including 
colon, stomach, tongue, esophagus, cervix, sweat glands, and 
the prostate [11]. In colorectal cancer however, its concentra-
tion is increased and the general distribution of the molecule 
on the cell surface is also altered. CEA is considered as one 
of the most clinically significant tumor markers for colorec-
tal cancer, providing information on prognosis, tumor recur-
rence, and metastasis [10, 11]. 
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  Vascular endothelial growth factor (VEGF) is a dimeric 
glycoprotein of 34-42 kDa. It is expressed by a variety of 
normal cells, but is significantly over-expressed by malig-
nant tumors (such as colorectal adenocarcinoma), where it 
can be produced by the tumor cells themselves or by stromal 
cells [12, 13]. This glycoprotein plays a crucial role in many 
pathologic conditions and malignancies because it stimulates 
capillary tube formation, endothelial cell proliferation, tumor 
invasion and metastasis, thereby playing an essential angio-
genic role pivotal for tumor growth and aggressiveness [13-
15]. 
  The aim of this study is to measure the levels of CEA and 
VEGF in serum and plasma respectively in order to deter-
mine whether they can play a role in detection and diagnosis 
of colorectal cancer in the Lebanese population. 
MATERIALS AND METHODOLOGY 
  Our study consisted of patients and controls, both of 
which are representatives of the Lebanese population with its 
cultural and religious diversity. The first group comprised of 
thirty-six patients with colorectal carcinoma (20 males and 
16 females, mean age 67 years, age range 24 to 90 years) 
diagnosed at the American University of Beirut Medical 
Center (AUBMC) between October 2004 through June 2007. 
The control group consisted of eight healthy volunteers (6 
males and 2 females, mean age 40 years; range 25 to 61) that 
were studied during the same period. Serum and plasma 
from the patients and controls were obtained and evaluated 
for CEA and VEGF levels. 
  At the time of enrollment in the study, 7 to 10 milliliters 
of whole blood were drawn from the anticubital vein from 
each patient preoperatively, and from each control individual 
after clinical evaluation. Blood samples were drawn sepa-
rately into vacutainers containing sodium ethylenediamine 2    The Open Clinical Cancer Journal, 2007, Volume 1  Dbouk et al. 
tetra-acetic acid (EDTA-Na) for plasma and non EDTA-Na 
vials for serum. The samples were then centrifuged at 3500 
rpm for 3 minutes (directly after extraction for plasma, and 
after waiting at room temperature for 20 to 30 minutes for 
serum), and then stored at -80° C until analyzed. 
  CEA serum concentration was determined by quantita-
tive enzyme-linked immunosorbent assay (ELISA) (IBL 
CEA ELISA, Immuno-biological laboratories, Hamburg, 
Germany). VEGF plasma concentration was also determined 
by quantitative ELISA (Quantikine, R&D Systems, Minnea-
polis, USA). All samples were run in duplicate. The experi-
ments were repeated three times and calculations were based 
on mean values in order to ensure accuracy. 
  Plasma samples instead of serum samples were used for 
VEGF levels in order to avoid inaccuracy resulting from the 
well known production of VEGF by platelets, thereby mak-
ing the results more reliable and reproducible [16]. 
  Statistical analysis was performed by Student’s t-test for 
independent samples using SPSS 15.0 for Windows statisti-
cal software, with  < 0.05 considered as statistically signifi-
cant. Analysis included the following variables: CEA and 
VEGF levels, patient gender, age, tumor location, lymph 
node involvement, and presence of distant metastasis. Serum 
levels of CEA and plasma levels of VEGF were considered 
as pathological when they exceeded the mean plus two stan-
dard deviations of the control groups. 
RESULTS 
  Patient characteristics are summarized in Table 1. CEA 
levels were assayed in all 36 patients, whereas VEGF levels 
were assayed in 27 of the 36 patients. The relatively small 
sample size is a reflection of the incidence rates of cancers in 
Lebanon, due to the small population size, as well as the low 
detection frequencies as many cancers go un-noticed or are 
diagnosed at terminal stages. Therefore, this provides direct 
evidence for the need to devise easy and cheap methods for 
cancer detection in the Lebanese population.  
  The cut-off values for both CEA and VEGF were calcu-
lated as the mean values obtained from the control cases plus 
2 standard deviations. CEA levels < 3.8 ng/ml and VEGF 
levels < 12.84 ng/ml were considered normal. 
  The median CEA levels in patients and controls were 
15.13 ng/ml (range 2.53 to 176.51 ng/ml) and 2.52 ng/ml 
(range 1.31 to 3.218 ng/ml), respectively. The median VEGF 
levels for patients and controls were 21.22 ng/ml (range 3.82 
to 55.82 ng/ml) and 4.52 ng/ml (range 1.375 to 9.61 ng/ml) 
respectively (Fig. 1). Forty-eight percent of the patients had 
lymph node metastasis and 50% of the patients had distant 
metastasis. Both metastatic groups had CEA and VEGF lev-
els that were higher than those of controls, but this difference 
was not statistically significant (p > 0.05). With respect to 
tumor differentiation, CEA and VEGF levels were near the 
cutoff levels in well-differentiated tumors, and much higher 
in moderately to poorly differentiated tumors, however, we 
were unable to include this in our study due to very limited 
number of patients with well-differentiated tumors (2 of 30) 
compared to moderate-poorly differentiated tumors (28 of 
30), thereby preventing statistical comparison. 
  Using the cut-off levels mentioned above, specificity was 
85.7% for CEA and 71.4% for VEGF, while sensitivity was 
58.3% for CEA and 63% for VEGF. Independently, both 
markers had a high positive predictive value of 95.4% and 
89.5% for CEA and VEGF respectively, and when com-
bined, their positive predictive was also relatively high at 
88%. The negative predictive value of these two markers 
was low, 28.5% for CEA and 33.3% for VEGF. The combi-
nation of both markers (using our cut-off values and those 
used in other studies) also gave a very low negative predic-
tive value at 28% (Table 2). 
DISCUSSION 
  Among the prognostic and diagnostic markers studied in 
colorectal cancer, the most significant are CEA and VEGF. 
They are linked to tumor growth and metastasis as well as 
other tumor properties [8, 11, 14]. VEGF plays a key role in 
angiogenesis, a highly complex process that is essential for 
tumor growth. Angiogenesis is regulated by various pro- and 
anti-angiogenic factors. One of the most important pro-
angiogenic factors is VEGF, which is secreted by a variety 
 
Fig. (1). Patient and normal control distribution depending on both CEA and VEGF levels: The patient distribution, for most patients, is 
clearly distinct from the normal samples for both CEA and VEGF. The horizontal line represents the CEA cut-off level at 3.8 ng/ml 
(log[CEA] = 0.58), while the vertical line is the VEGF cut-off level of 12.84 ng/ml. 
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of tumors and is regulated by the tumor cells themselves as 
well as by the tumor microenvironment [12, 14]. CEA, on 
the other hand, plays an important role in tumor metastasis, 
especially to the liver, where it mediates tumor cell adhesion 
to new sites [11]. 
  Determining the relationship between these two and colo-
rectal cancer, has been the focus of several studies. The re-
sults were variable in terms of their role in this tumor as ei-
ther diagnostic or prognostic markers. Schiemann and 
coworkers showed higher levels of CEA in hereditary non-
polyposis colorectal cancer, and lower levels in sporadic 
colorectal cancer [18]. A review of various studies concludes 
that CEA has little diagnostic value; rather it has significant 
prognostic value in determining patient outcome following 
surgery or chemotherapy [10]. Still other studies show that 
the prognostic role of CEA in colorectal cancer may be en-
hanced with simultaneous use of other markers [18-20]. A 
recent study by Ferroni and coworkers showed that the use 
of tissue CEA and VEGF levels is potentially useful for the 
prognosis of colorectal cancer patients [21]. 
  Studies have also produced conflicting results concerning 
VEGF as a diagnostic marker in colorectal cancer. Broll and 
coworkers demonstrated that VEGF has a low sensitivity of 
36% [15], whereas our study shows a higher VEGF sensitiv-
ity (63%). Other studies showed that VEGF has a significant 
prognostic role by affecting the tumor’s metastatic potential, 
and by correlating with response to treatment and survival 
[16, 22, 23].  Preoperative and postoperative VEGF levels 
were also shown to correlate with prognosis [24]. Still other 
studies showed that the combination of CEA and VEGF in-
creases the sensitivity in detecting colorectal cancer [15, 21, 
25]. 
  This study compares the significance of CEA and VEGF 
blood levels, both independently and in combination, as di-
agnostic markers for colorectal cancer. We found VEGF 
levels to be much higher in our patient group than in controls 
when compared to CEA. Most patient CEA levels, in con-
trast, clustered relatively close to the normal cut-off value of 
3.8 ng/ml (or log[CEA] = 0.58) (Fig. 1). Furthermore, our 
findings differ from those of other studies, which demon-
strate that the combination of both markers increases their 
positive predictive value. In our study, the use of individual 
markers gave a higher positive predictive value than the 
combination of the two markers at the selected cutoff limits. 
Lowering the CEA cut-off value to the 2.5 ng/ml figure used 
in a multitude of other studies as the cut-off value of prefer-
ence for CEA, while maintaining our VEGF cut-off value of 
12.84 ng/ml, increased the combined positive predictive 
value from that observed with our cutoffs (88%) to 89.5%. 
The low negative predictive values of these two markers in 
the Lebanese population indicates that results from such test 
should serve only as preliminary tests, and should be fol-
lowed by others in case of suspicion of cancer or family his-
tory. 
CONCLUSION 
  This study indicates that the combination of serum CEA 
and plasma VEGF levels, interpreted with the cut-off levels 
used here, appears to have value in the detection of colorec-
tal cancer in our group of patients, and potentially for Leba-
Table 1.  Significance of CEA and VEGF Values of Patients According to Tumor Characteristics 
Features 
Patients with 
CEA 
CEA (ng/ml) 
Mean 
p value 
Patients with 
VEGF 
VEGF (ng/ml) 
Mean 
p value 
Normal Group  8  3.8  -  8  12.84  - 
Sex 
Male 20 20.39  17 17.34 
Female 16  8.67 
0.286 
10 27.84 
0.059 
Age 
>55 31  15.74  24  21.36 
55 4  10.71 
0.774 
3 20.13 
0.889 
Tumor Location 
Colon 23 18.59  17  20.1 
Rectum 12  7.67 
0.357 
10 21.38 
0.821 
Distant Metastasis 
Yes 17  22.82  14 23.6 
No 17  7.56 
0.184 
13 18.67 
0.372 
Lymph node involvement 
Yes 14  25.52  13  22.77 
No 15  6.23 
0.151 
12 18.49 
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nese and other patients. This is by no means a specific test 
since CEA itself may be detected in a variety of tumors such 
as lung and breast carcinoma, among others [11]. We con-
clude, based on the lack of statistically significant diagnostic 
value from our study, and as a conclusion of various studies 
in the literature, that the main value of these two markers 
still lies in the fact that they provide greater insight into 
prognosis of colorectal cancer. Even though our study did 
not show this, the lack of prognostic value can be traced to 
the small patient number not to absence of prognostic corre-
lation, as values between controls and patients, as well as 
between the different classifications of patients, were clearly 
different in observation, but not so statistically as overall. 
  If CEA and VEGF levels are to be used for diagnostic 
purposes, they should be coupled with colonoscopy and bi-
opsy, which remain the golden standards in detection and 
diagnosis of colorectal carcinoma, and possibly with various 
stool screening approaches such as fecal occult blood and 
other potential stool markers [26]. Concomitant high CEA 
and VEGF levels can potentially select out a subgroup of 
individuals who may require either earlier or more frequent 
screening colonoscopy. Until the time comes when there will 
be one specific marker for colorectal cancer, additional mo-
lecular studies on a larger number of patients are needed to 
validate the above results. 
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